German company apoQlar has announced its plans to raise Series A funding after receiving FDA 510(k) clearance for its VSI HoloMedicine platform.
It is a mixed reality offering that helps surgeons plan for procedures using 3D holographic technology. The platform enables surgeons to turn radiographic images such as PET, Angio CT, SPECT, CBCT, CT and MRI scans into 3D holograms to examine before surgery.
The Hamburg-based company said it has now received medical certifications in 30 countries.
Through its subsidiary in Miami, Florida, apoQlar will distribute its HoloMedicine platform in the US during the second quarter of 2023, and the prospective Series A raise will help scale its platform.
It is significant to note that apoQlar isn't the only immersive technology platform aiming to help surgeons during the surgery process.
Augmedics' xvision Spine System, which received FDA clearance in 2019, provides an augmented reality tool that gives surgeons a 3D image of spinal anatomy directly in their line of sight during surgery. In 2022, the company had announced a $36 million Series C funding.
Join the HealthXL Masterclass on the ‘Future EU Regulations for AI in Medical Devices’ on 13th December. Click here to Request to Join.
Click here to read the original news article.